{# max-image-preview:large is what makes an article eligible for the big-image card in Google Discover — without it Google may only show a thumbnail. #} {# ── Google Preferred Sources ──────────────────────────────────────────── Readers who mark us as a preferred source get our fresh articles prioritised in Top Stories, Discover and Google News. Only domain- and subdomain-level sites are eligible — blog.alfafinder.com qualifies, a /news/ subdirectory would not. #}

Zydus Lifesciences — Latest News

Every announcement Zydus Lifesciences has filed with the exchanges that we have reported, newest first. Each story links the original filing.

NSE: ZYDUSLIFE BSE: 532321 Pharmaceuticals & Biotechnology 2 stories

Price

₹1114

Market Cap

₹1.12L Cr

Revenue TTM

₹27,148.40 Cr

P/E (TTM)

22.24×

Sector 44.55×

Reference data from Trendlyne, as of the most recent story. Not a valuation or a recommendation.

Product Launched · 2
Product Launched

Zydus Lifesciences Launches REVAHALE, India's First Once-Daily Nebulised LAMA for COPD

Zydus Lifesciences launches REVAHALE, India's first once-daily nebulised LAMA for COPD, offering 24-hour relief. Company TTM revenue stands at 27,148…
Product Launched

Zydus Lifesciences and Apollo Hospitals Partner to Launch Shield Multi-Cancer Detection Test

Zydus Lifesciences signs MoU with Apollo Hospitals to launch the Shield™ Multi-Cancer Detection test in India, targeting 10 cancer types via single b…

Track Zydus Lifesciences in real time

ALFA Finder watches NSE & BSE filings 24/7 and alerts you the moment Zydus Lifesciences files something material.

Start Free — 15-day trial
{# ── Promo popup — fires 5s after first page load per session. NEVER fires for visitors arriving from a search engine: a full-viewport overlay on a news article is an intrusive interstitial, and Google News policy is explicit that promotional material must not exceed the content. Direct, social and referral traffic still sees it. ─────────── #}